-
Many Ineligible for New Alzheimer’s Drugs: Study -
New Case Report Links 1 Death to New FDA-Approved Alzheimer’s Drug
-
Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval
-
Lecanemab May Reverse Alzheimer’s Disease, But 3 Deaths Raise Questions
-
FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab
